Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease. (5th January 2015)

• Record Type: Journal Article
• Authors: Bochennek, K.; Balan, A.; Müller-Scholden, L.; Becker, M.; Farowski, F.; Müller, C.; Groll, A. H.; Lehrnbecher, T.
• Is Part Of: Journal of antimicrobial chemotherapy. Volume 70:Number 5(2015:May)
• Page Start: 1527
• Page End: 1530
• Publication Date: 2015-01-05
• Subjects: child -- cancer -- haematopoietic stem cell transplantation; Anti-infective agents -- Periodicals; Chemotherapy -- Periodicals; 615.58
• DOI: 10.1093/jac/dku544
• Languages: English
• ISSNs: 0305-7453

Abstract

Abstract: Background: Current guidelines recommend antifungal prophylaxis for children at high risk for invasive fungal disease (IFD), but the use of polyenes and triazoles may not be feasible in some patients due to toxicities and drug–drug interactions. Micafungin is well tolerated, with intravenous daily dosing being the current standard. Recent reports indicate safety and efficacy of intermittent dosing of micafungin. Methods: We analysed safety, efficacy and micafungin serum concentrations of children at high risk for IFD receiving prophylactic micafungin between 3 and 4 mg/kg twice weekly. All children were intolerant or had contraindications to polyenes and triazoles. Results: A total of 21 children (median age = 9 years) at high risk for IFD were included in the analysis. No significant clinical adverse event occurred, and end of treatment values of parameters of renal and hepatic function in serum were not different from baseline. Proven or probable breakthrough IFD did not occur in any of the patients. In 9 out of 11 patients in whom plasma micafungin concentrations were assessed, the first trough concentration exceeded 150 ng/mL, a concentration proposed to be effective for prophylaxis. Conclusions: Our data indicate that micafungin administered twice weekly at a dosage of 3–4 mg/kg of bodyweight could be a convenient, safe and efficient alternative for antifungal prophylaxis in children at high risk for IFD.